Lv62
3110 积分 2023-04-23 加入
Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway
17天前
已完结
Enhancing anti-CD274 (PD-L1) targeting through combinatorial immunotherapy with bispecific antibodies and fusion proteins: from preclinical to phase II clinical trials
17天前
已完结
Sharks give a handle to potent anti-tumor multiparatopic antibodies inducing membrane depletion of PD-L1
22天前
已完结
Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation
28天前
已完结
Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity
1个月前
已完结
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1
1个月前
已完结
Beyond Inhibition Against PD-1/PD-L1 Pathway: Development of PD-L1 Inhibitors Targeting Internalization and Degradation of PD-L1
1个月前
已完结
Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer
1个月前
已完结
Advances in the Chemistry of Natural and Semisynthetic Topoisomerase I/II Inhibitors
2个月前
已完结
Screening of Candidate Inflammatory Markers of Epithelial Cells in Hepatocellular Carcinoma Based on Integration Analysis of TCGA/ICGC Databases and Single-cell Sequencing
3个月前
已完结
皖公网安备34019202002308
